With the outbreak of coronavirus, AVMI has embarked on public education on the risk of the pandemic and further been persuading African leaders about the need to serious prioritize manufacturing of vaccines instead of depending on external supply.
In this snapshot interview, Patrick Tippoo, Executive Director at the Africa Vaccine Manufacturing Initiative, explains that vaccine manufacturing is a complex, time-consuming exercise requiring considerable commitment, and financial as well as technical resources. He further underscores the fact that the capital investment required is considerable and equally essential is a long-term future view for the health system and population in Africa.
Here are the interview excerpts:
What are your views about the global politics surrounding the coronavirus vaccines? Where does Africa stand in this case?
It’s unfortunate that Covid-19 vaccines have become politicized leading to a situation where some regions and countries are lagging so far behind others with respect to vaccination coverage. As we’ve seen Africa in particular has been affected very negatively in this regard.
In your view, should vaccines and related coronavirus medicines be politicized, in the first place, in this era of global pandemic?
In pandemic situations like we are experiencing now it is regrettable that vaccines have become so politicized. Ideally one would expect that every effort would be made to ensure that vaccines are made available equitably to ensure that there is no delay in getting the pandemic under control across the globe.
Within the context of current trade wars, for example between United States and China, and/or between China and India, what do you think be done to remove distribution barriers for vaccines in regions such as Africa?
Understandably, I don’t think that trade wars between certain countries are a major reason for Africa not having accessed vaccines in proportion to other geographies. As I understand, the reason why Africa does not have access to the volume of vaccines is primarily due to the fact that African countries could not purchase vaccines in advance and are dependent on facilities like COVAX. COVAX in turn has had challenges in securing enough vaccines for distribution into countries which signed up.
It implies that Africa will have difficulty in accessing the coronavirus vaccines? What do you suggest African leaders critically look redirecting funds to their health systems and health research (R&D)?
African leaders need to rally together to ensure that no effort is spared in facilitating and supporting the building of large scale vaccine manufacturing capacity on the continent. The recent African Vaccine Manufacturing Summit in April is an encouraging start. Focus needs to be on developing real vaccine R&D capacity which leads to products. This requires substantial investment and a long-term commitment.
Furthermore, governments need to commit to buy locally made vaccines and work individually and collectively in creating guaranteed access to African vaccine markets. What makes this 10 times more difficult is that around 40 of the 54 African countries receive the vaccines from UNICEF financed by GAVI.
Business is business and making profit is the basis for business. Do pharmaceutical firms have to be profit-oriented in the global health crisis?
A balance should be struck. Making a profit is vitally important for business sustainability. However, in a global health crisis such as Covid-19 companies should not be exploiting the situation to generate maximum profits. Indeed, some companies producing Covid-19 vaccines have demonstrated that this is possible, charging a few dollars per vaccine dose.
What could be the possible roles of African Union (AU) and other sub-regional organizations?
- Demand certainty and access to markets are vital. African governments, sub-regional organizations and the AU should work together to create regional or pooled markets and guarantee purchase of locally produced vaccines. This is possibly the most important enabler of building and sustaining local vaccine manufacturing capacity.
- Accelerate efforts to create streamlined regulatory processes for speedier accreditation of vaccine manufacturing facilities and licensing product to ensure that vaccines can be available in the fastest time possible. Delays in getting market authorization for product by National Regulatory Authorities have a direct negative impact on cash flows and creates real barriers to building sustainable capacities.
- Another essential contribution would be the mobilization resources and/or creation of enabling environments for resources to be unlocked and discharged as vaccine production is capital intensive and requires access to innovative funding streams over 10-20 years.
- Incentivization of technology transfer partnerships to achieve capacity building in the fastest possible time.
- Invest in skills development programs specifically geared to creating a workforce skilled in vaccine development and manufacturing know-how.
In summary, no effort should be spared in working to ensure that in a pandemic situation vaccines there is no delay in getting vaccines to where they are most needed in the fastest possible time.
